A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations

NCT07178717 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Colo-rectal Cancer

Interventions

DRUG: Rechalange with bevacizumab + encorafenib

Sponsor

Vall d'Hebron Institute of Oncology